Small intestinal bacterial overgrowth recurs in a significant proportion of patients after successful treatment. Antimicrobial protocols clear the overgrowth but do not address the conditions that allowed it. Gastric acid is the primary barrier preventing bacteria from reaching the small intestine. When acid production is insufficient, the barrier fails and SIBO returns. Assessing gastric acid function can identify whether a compromised acid barrier is part of the recurrence pattern.
You were diagnosed with SIBO. You completed a course of rifaximin, or a herbal antimicrobial protocol, or both. Your symptoms improved. For weeks or months, you felt better. Then the bloating returned. The gas came back. The breath test turned positive again. You started another round of treatment. And another. The cycle continues and nobody can tell you why.
This is one of the most common and frustrating patterns in functional medicine. SIBO recurrence rates in published studies range from 12% to over 40% within a year of successful treatment, depending on the population and the definition used. For many patients, the number feels closer to inevitable. The question they all ask is the same: why does it keep coming back?
Antimicrobial treatment for SIBO targets the overgrowth itself. It kills or suppresses the bacteria in the small intestine. When it works, symptoms improve because the bacterial population is reduced. But the treatment does not address why the bacteria were there in the first place.
Bacteria do not spontaneously appear in the small intestine. They are ingested with every meal, every sip of water, every swallow. Under normal conditions, two primary mechanisms prevent them from coloniZing the small intestine. The first is gastric acid. The second is small intestinal motility. If either barrier fails, bacteria survive and accumulate. If both fail, recurrence is almost certain regardless of how many rounds of treatment are completed.
Gastric acid at a pH below 3 kills approximately 99% of ingested bacteria. This antimicrobial function is one of the stomach's primary roles. Every meal introduces microorganisms from food, water, the oral cavity, and the environment. In a stomach producing adequate acid, the vast majority of these organisms are destroyed before they reach the duodenum.
When acid production is insufficient, bacterial survival increases dramatically. More organisms pass through the stomach alive. They arrive in the small intestine in numbers that overwhelm the normal clearing mechanisms. If motility is also impaired, those organisms remain, attach, and proliferate. The overgrowth that the breath test detects is the consequence of a failed upstream barrier.
The association between reduced gastric acid and bacterial overgrowth is well established. Lo and Chan published a meta-analysis in Clinical Gastroenterology and Hepatology in 2013 showing that PPI use was associated with a significantly increased risk of SIBO. The odds ratio was 2.28, meaning PPI users were more than twice as likely to develop SIBO as non-users.
Earlier foundational work by Giannella, Broitman, and Zamcheck in 1972 demonstrated that bacterial colonization of the small intestine increases as gastric pH rises. More recent studies have confirmed that patients with autoimmune atrophic gastritis, who have severely reduced or absent acid production, have markedly higher SIBO prevalence than age-matched controls.
The mechanism is consistent across all of these studies: less acid means more bacteria survive the stomach. More surviving bacteria means higher risk of small intestinal colonization. The acid barrier is not the only factor in SIBO pathogenesis, but it is one of the most important and one of the most frequently overlooked.
The standard SIBO workup includes a breath test and an antimicrobial protocol. It typically does not include an assessment of gastric acid function. There are practical reasons for this. Until recently, measuring gastric acid required invasive nasogastric intubation, which was impractical in an outpatient setting. Blood markers like serum pepsinogen provide indirect clues but do not measure actual acid output. The baking soda challenge and the betaine HCl challenge, both widely promoted online, produce no quantitative data and have no clinical validation.
The result is that most SIBO patients are treated without ever knowing whether their acid barrier is intact. If it is not, the treatment addresses the consequence while leaving the cause untouched. The overgrowth clears. The barrier remains broken. The overgrowth returns.
The Heidelberg pH Capsule measures gastric acid secretion and reacidification capacity in real time. For the SIBO patient who has relapsed after treatment, this assessment answers a specific question: is the acid barrier functional?
If acid production is normal, the recurrence likely has a different primary driver, such as impaired motility, structural abnormalities, or immune deficiency. The clinician can focus the investigation accordingly.
If acid production is insufficient, the barrier failure becomes part of the management strategy. Supporting or restoring acid production becomes as important as treating the overgrowth itself. Without this data, the clinician is working with incomplete information and the patient is likely headed for another relapse.
If your SIBO keeps returning despite successful treatment, an incomplete picture may be part of the reason. A professional gastric acid assessment can determine whether your acid barrier is contributing to the recurrence pattern.
Take our 2-minute self-assessment quiz to see whether low stomach acid may be relevant to your situation. Or find a practitioner near you who offers the Heidelberg test.
The Heidelberg pH Capsule is a Class I medical device, 510(k)-exempt, listed with the U.S. Food and Drug Administration under 21 CFR §876.1400. Listing of a device does not denote FDA approval, clearance, or endorsement.